B
Black Diamond Therapeutics D
D
BDTX
1.87000
USD
0.27
(16.51%)
مغلق
حجم التداول
186,733
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
107,154,317
العنوان: Black Diamond Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding ofcancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor,is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
